International Stem Cell Corp Enters Material Agreement
Ticker: ISCO · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1355790
| Field | Detail |
|---|---|
| Company | International Stem Cell Corp (ISCO) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $2,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
ISC signed a big deal, could be good or bad, need more info.
AI Summary
International Stem Cell Corporation (ISC) entered into a material definitive agreement on September 15, 2025. The company also created a direct financial obligation or an obligation under an off-balance sheet arrangement. Specific details of the agreement and financial obligations are not provided in this filing.
Why It Matters
This filing indicates a significant new agreement for International Stem Cell Corp, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and financial obligation, but lacks specific details, creating uncertainty.
Key Players & Entities
- International Stem Cell Corporation (company) — Registrant
- September 15, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 9745 Businesspark Ave, San Diego, California 92131 (address) — Principal executive offices
- 760-940-6383 (phone_number) — Business phone
FAQ
What is the nature of the material definitive agreement entered into by International Stem Cell Corporation?
The filing states that International Stem Cell Corporation entered into a material definitive agreement on September 15, 2025, but does not provide specific details about the agreement itself.
What type of financial obligation did International Stem Cell Corporation create?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics are not detailed.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 15, 2025.
What is the principal executive office address for International Stem Cell Corporation?
The principal executive office address for International Stem Cell Corporation is 9745 Businesspark Ave, San Diego, California 92131.
What is the SIC code for International Stem Cell Corporation?
The Standard Industrial Classification (SIC) code for International Stem Cell Corporation is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-09-16 09:57:40
Key Financial Figures
- $2,500,000 — of the loan (in the principal amount of $2,500,000) from Dr. Semechkin to the Company that
Filing Documents
- intlstemcell_8k.htm (8-K) — 28KB
- intlstem_ex1001.htm (EX-10.1) — 13KB
- 0001683168-25-007018.txt ( ) — 201KB
- isco-20250915.xsd (EX-101.SCH) — 3KB
- isco-20250915_lab.xml (EX-101.LAB) — 33KB
- isco-20250915_pre.xml (EX-101.PRE) — 22KB
- intlstemcell_8k_htm.xml (XML) — 3KB
01
Item 1.01 Entry into a Material Definitive Agreement. On September 15, 2025, International Stem Cell Corporation (the "Company") and Dr. Andrey Semechkin agreed to extend (until September 15, 2026) the maturity date of the loan (in the principal amount of $2,500,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated September 15, 2024 (the "Original Note"), and which would have been due on September 15, 2024. Dr. Semechkin is the Company's Co-Chairman and Chief Executive Officer. The outstanding principal amount under the Note accrues interest at a rate of five and a half percent (5.5%) per annum. The Note is due and payable September 15, 2026 but may be pre-paid by the Company without penalty at any time. The foregoing summary of the Note is qualified in its entirety by reference to the full text of the form of Note filed as Exhibit 10.1 to this Current Report on Form 8-K.
03
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of the Registrant. The information disclosed in Item 1.01 is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Form of Note issued on September 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTERNATIONAL STEM CELL CORPORATION Date: September 16, 2025 By: /s/ Russell Kern Russell Kern Executive Vice President, Chief Scientific Officer and Principal Financial Officer 3